FDA Issues Warning Letter for Lancome Anti-Aging Products
September 26, 2012
The U.S. Food and Drug Administration (FDA) has issued a warning letter to cosmetic company Lancôme USA, a subsidiary of L’Oréal, regarding the advertising of various anti-aging skin care products.
The FDA’s warning letter states that “the claims on your web site indicate that these products are intended to affect the structure or any function of the human body, rendering them drugs,” and that a new drug cannot be marketed in the U.S. without obtaining FDA approval first. The FDA’s letter further states that the products at issue “are not generally recognized among qualified experts as safe and effective” for the advertised uses. Therefore, the FDA informed the company that their product claims appear to be in violation of section 201 of the Federal Food, Drug, and Cosmetic Act.
Some of the products included in the FDA’s warning letter are:
- Génifique Youth Activating Concentrate, Génifique Eye Youth Activating Eye Concentrate, and Génifique Cream Serum Youth Activating Cream Serum
- Génifique Repair Youth Activating Night Cream
- Absolue Precious Cells Advanced Regenerating and Reconstructing Cream SPF 15 Sunscreen
- Absolue Eye Precious Cells Advanced Regenerating and Reconstructing Eye Cream and Absolue Night Precious Cells Advanced Regenerating and Reconstructing Night Cream
- Rénergie Microlift Eye R.A.R.E.™ Intense Repositioning Eye Lifter
The FDA also requested that Lancôme take action to correct all violations, and gave the company 15 days from the receipt of the letter to issue a response.
Speak with a Consumer Fraud Attorney
Have you purchased any of Lancôme’s anti-aging creams, concentrates or serums? If so, the consumer lawyers here at Gibbs Law Group are interested in hearing about product issues that may have affected you. For more information, please call us toll free at 1-800-254-9493 or fill out the form to the right.